Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression

[1]  F. Hirsch,et al.  Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress? , 1997, Lung cancer.

[2]  F. Hirsch,et al.  88 Oral etoposide (VP-16) every 3 wks. or continuously to elderly patients with small cell lung cancer (SCLC): Preliminary results of a randomized study , 1997 .

[3]  R. Souhami,et al.  Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. , 1997, Journal of the National Cancer Institute.

[4]  D. Girling.  Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial , 1996, The Lancet.

[5]  F. Hirsch,et al.  Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party. , 1996, British Journal of Cancer.

[7]  R. Stephens,et al.  Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified? Medical Research Council Lung Cancer Working Party. , 1994, Lung cancer.

[8]  H. Hansen,et al.  Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Coldman,et al.  Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  H. Hansen,et al.  Management of small cell lung cancer: a summary of the Third International Association for the Study of Lung Cancer Workshop on Small Cell Lung Cancer. , 1990, Journal of the National Cancer Institute.

[11]  H. Earl,et al.  Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. , 1989, British Journal of Cancer.

[12]  L. Case,et al.  Improvement of long-term survival in extensive small-cell lung cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  C. Perez,et al.  A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. Hirsch,et al.  The superiority of combination chemotherapy including etoposide based on in vivo cell cycle analysis in the treatment of extensive small-cell lung cancer: a randomized trial of 288 consecutive patients. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Hansen,et al.  Chemotherapy versus chemotherapy plus irradiation in limited small cell lung cancer. Results of a controlled trial with 5 years follow-up. , 1986, British Journal of Cancer.

[16]  R. Stahel,et al.  Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature. , 1984, European journal of cancer & clinical oncology.

[17]  F. Hirsch,et al.  Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. , 1983, Cancer research.

[18]  J. Ducore,et al.  Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. , 1983, Cancer research.

[19]  L. Kanz,et al.  Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  M. Fukuoka,et al.  Dose escalation study of carboplatin with fixed‐dose etoposide plus granulocyte‐colony stimulating factor in patients with small cell lung carcinoma: A study of the lung cancer study group of west Japan , 1996, Cancer.

[21]  J. Radford,et al.  Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. , 1992, European journal of cancer.

[22]  F. Hirsch,et al.  Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  F. Hirsch,et al.  Original article: Combination chemotheraphy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens , 1991 .